Silka Marketer Scratches Monograph Claim Itch In NAD Review

In response to a National Advertising Division inquiry on efficacy claims challenged by Bayer Healthcare, the US subsidiary of Mexican firm Genomma Lab Corp. said some claims for its Silka athlete's foot treatment were discontinued "but continued to air due to a miscommunication in its marketing department."

Genomma Lab USA Inc. is straight on the OTC monograph for antifungal products, but the firm is straightening out its process for making sure ads for its Silka athlete's foot treatment comply with the regulation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography